Carbenoxolone, a drug that blocks an enzyme involved in cortisol production, lowers cortisol regeneration throughout the body in obese men, but it does not significantly reduce cortisol regeneration in abdominal fat tissue or improve how the body responds to insulin.

55

Pro

0

Against

Evidence from Studies

Supporting (1)

55

Community contributions welcome

55

Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.

Randomized Controlled Trial

Human

2005 Mar

The study found that a drug called carbenoxolone lowers cortisol in the whole body but doesn’t stop it from being made in belly fat, and it doesn’t help obese men become more sensitive to insulin. So, the drug doesn’t fix the insulin problem, even though it changes cortisol levels.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.

Score: 55

DOI: 10.2337/DIABETES.54.3.872

Similar Assertions

In obese men, a drug called carbenoxolone does not block a specific enzyme in fat tissue that regulates stress hormones, suggesting that existing drugs of this type are not strong enough or cannot reach the fat tissue effectively to change metabolism.

55

0

80%

In men with obesity, the drug carbenoxolone does not improve insulin sensitivity as effectively as it does in men with normal weight, suggesting that obesity alters how the body responds to this type of treatment.

55

0

77%